UK Markets open in 33 mins

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
787.20-1.40 (-0.18%)
At close: 04:59PM CEST
Full screen
Previous close788.60
Open781.00
Bid786.30 x 0
Ask786.70 x 0
Day's range769.00 - 788.50
52-week range526.30 - 834.50
Volume2,159,239
Avg. volume1,961,168
Market cap1.794T
Beta (5Y monthly)0.32
PE ratio (TTM)39.40
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield10.40 (1.39%)
Ex-dividend date25 Mar 2022
1y target estN/A
  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 27 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiat

  • Globe Newswire

    Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency

    Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1 Atlanta, Georgia (US), 12 June 2022 – Today, Novo Nordisk announced results of once-weekly Sogroya® (somapacitan) injection in helping children achieve growth targets of annualised height velocity (AHV).1 These phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented today at the Endocrin

  • Globe Newswire

    Novo Nordisk A/S:

    Novo Nordisk – major shareholder announcement Bagsværd, Denmark, 7 June 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section